Clinical trials recruiting for Gastric Adenocarcinoma
13
Recruiting trials
29
US states with sites
10
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| ASP2138 | 1 |
| AVA6103 | 1 |
| Atezolizumab | 1 |
| BHB810 | 1 |
| Bevacizumab | 1 |
| Capecitabine | 1 |
| DISP-10 | 1 |
| Docetaxel | 1 |
| Dostarlimab | 1 |
| Extended Dosing Interval - A | 1 |
| Extended Dosing Interval - B | 1 |
| Extended Dosing Interval - C | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 6 |
| Texas | 6 |
| New Jersey | 4 |
| New York | 4 |
| Virginia | 4 |
| Arizona | 3 |
| Florida | 3 |
| North Carolina | 3 |
| Ohio | 3 |
| Pennsylvania | 3 |
| Washington | 3 |
| District of Columbia | 2 |
Top cities
Fairfax, Virginia 4New York, New York 4Dallas, Texas 3Duarte, California 3Seattle, Washington 3Boston, Massachusetts 2Cincinnati, Ohio 2Cleveland, Ohio 2Durham, North Carolina 2East Brunswick, New Jersey 2
Self-screener
Recruiting trials
- A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- A Study of KK2269 in Adult Participants With Solid Tumors
- A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
- AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
- Evaluating Novel Therapies in ctDNA Positive GI Cancers
- First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
- Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Related conditions
Trials recruiting for Gastric Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Lung cancer 2180Colorectal cancer 1359Esophageal Adenocarcinoma 15Pancreatic Adenocarcinoma 49Non-small cell lung cancer 507Gastroesophageal Junction (GEJ) Adenocarcinoma 3Gastroesophageal Adenocarcinoma 5Rectal Adenocarcinoma 23Metastatic Solid Tumor 22
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Gastric Adenocarcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.